ChemoCentryx (NASDAQ:CCXI) Sets New 12-Month High at $40.35

ChemoCentryx Inc (NASDAQ:CCXI) shares reached a new 52-week high during mid-day trading on Thursday . The stock traded as high as $40.35 and last traded at $39.82, with a volume of 28325 shares trading hands. The stock had previously closed at $37.65.

Several equities research analysts recently weighed in on the company. Raymond James upped their price target on ChemoCentryx from $17.00 to $56.00 and gave the stock a “strong-buy” rating in a research note on Tuesday, November 26th. HC Wainwright raised their price objective on ChemoCentryx from $23.00 to $40.00 and gave the stock a “buy” rating in a research note on Tuesday, November 26th. BidaskClub cut ChemoCentryx from a “buy” rating to a “hold” rating in a research report on Tuesday, January 7th. JPMorgan Chase & Co. increased their target price on ChemoCentryx from $14.00 to $28.00 and gave the stock a “positive” rating in a research report on Tuesday, November 26th. Finally, Zacks Investment Research cut ChemoCentryx from a “buy” rating to a “hold” rating in a research report on Friday, January 3rd. Three equities research analysts have rated the stock with a hold rating, six have issued a buy rating and one has assigned a strong buy rating to the stock. ChemoCentryx has an average rating of “Buy” and an average price target of $40.29.

The company has a debt-to-equity ratio of 0.32, a current ratio of 3.12 and a quick ratio of 3.12. The firm has a 50-day moving average of $34.32 and a 200-day moving average of $14.54. The stock has a market cap of $2.20 billion, a PE ratio of -53.53 and a beta of 2.28.

ChemoCentryx (NASDAQ:CCXI) last released its earnings results on Monday, November 4th. The biopharmaceutical company reported ($0.22) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.28) by $0.06. ChemoCentryx had a negative return on equity of 88.76% and a negative net margin of 143.30%. The firm had revenue of $10.58 million during the quarter, compared to analysts’ expectations of $7.83 million. Equities analysts forecast that ChemoCentryx Inc will post -0.98 EPS for the current fiscal year.

In other ChemoCentryx news, Treasurer Markus J. Cappel sold 86,311 shares of the firm’s stock in a transaction that occurred on Monday, January 13th. The stock was sold at an average price of $37.09, for a total transaction of $3,201,274.99. Following the completion of the transaction, the treasurer now owns 162,558 shares in the company, valued at approximately $6,029,276.22. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, CEO Thomas J. Schall sold 279,166 shares of the firm’s stock in a transaction that occurred on Tuesday, November 26th. The shares were sold at an average price of $31.55, for a total value of $8,807,687.30. Following the transaction, the chief executive officer now owns 2,508,021 shares of the company’s stock, valued at approximately $79,128,062.55. The disclosure for this sale can be found here. Insiders have sold a total of 1,161,538 shares of company stock valued at $37,814,838 in the last 90 days. 12.20% of the stock is currently owned by company insiders.

Several large investors have recently bought and sold shares of CCXI. A.R.T. Advisors LLC grew its stake in ChemoCentryx by 9.6% during the 2nd quarter. A.R.T. Advisors LLC now owns 26,176 shares of the biopharmaceutical company’s stock worth $243,000 after buying an additional 2,300 shares during the last quarter. Parametric Portfolio Associates LLC lifted its stake in ChemoCentryx by 4.2% during the second quarter. Parametric Portfolio Associates LLC now owns 57,809 shares of the biopharmaceutical company’s stock worth $538,000 after purchasing an additional 2,319 shares in the last quarter. Tower Research Capital LLC TRC acquired a new stake in shares of ChemoCentryx in the second quarter valued at $29,000. SG Americas Securities LLC raised its stake in ChemoCentryx by 26.0% in the third quarter. SG Americas Securities LLC now owns 25,418 shares of the biopharmaceutical company’s stock valued at $172,000 after buying an additional 5,247 shares in the last quarter. Finally, JPMorgan Chase & Co. grew its holdings in shares of ChemoCentryx by 104.2% during the second quarter. JPMorgan Chase & Co. now owns 11,191 shares of the biopharmaceutical company’s stock worth $100,000 after purchasing an additional 5,710 shares during the last quarter. 60.72% of the stock is owned by institutional investors and hedge funds.

ChemoCentryx Company Profile (NASDAQ:CCXI)

ChemoCentryx, Inc, a clinical-stage biopharmaceutical company, develops new medications for inflammatory and autoimmune diseases, and cancer in the United States. The company targets the chemokine and chemoattractant systems to discover, develop, and commercialize orally-administered therapies. Its lead drug candidate is Avacopan, an orally-administered complement inhibitor of the complement C5a receptor (C5aR), is in Phase III development for the treatment of anti-neutrophil cytoplasmic auto-antibody-associated vasculitis.

Further Reading: What does the Producer Price Index (PPI) tell investors?

Receive News & Ratings for ChemoCentryx Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ChemoCentryx and related companies with MarketBeat.com's FREE daily email newsletter.